It was an honor to take part last week in a special NIH program to bid Dr. Anthony Fauci farewell and wish him the very best as he prepares to step down this month as director of the National Institute of Allergy and Infectious Diseases (NIAID). During this two-hour program, Tony reflected on his 54-year career of public service, advising seven U.S. presidents, and following the science through several major infectious disease outbreaks, from HIV to Ebola to COVID-19. In my brief introductory remarks, I stated that Tony has been a constant source of knowledge and inspiration for me and other NIH leaders. No send-off could adequately express our gratitude. This photo shows me offering my congratulations immediately after Tony finished addressing those in attendance. The live program was held on December 16 in NIH’s Wilson Hall and was also available for NIH staff to attend in real-time via videocast. Credit: NIH
It was an honor to testify on the President’s FY 2023 NIH budget before the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies Committee. Also testifying from NIH were five institute directors: Richard Hodes, National Institute on Aging; Nora Volkow, National Institute on Drug Abuse; Gary Gibbons, National Heart, Lung, and Blood Institute; Tony Fauci, National Institute of Allergy and Infectious Diseases; and Josh Gordon, National Institute of Mental Health. The hearing took place on May 17, 2022 in the Dirksen Senate Office Building in Washington, D.C.
On May 11, I was pleased to appear before the U.S. House of Representatives Subcommittee on Labor, Health and Human Services, Education, and Related Agencies to discuss NIH’s budget request for Fiscal Year 2023. Joining me (left to right) were leaders of several NIH institutes: Nora Volkow, National Institute on Drug Abuse; Tony Fauci, National Institute of Allergy and Infectious Diseases; Diana Bianchi, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Doug Lowy, National Cancer Institute; and Gary Gibbons, National Heart, Lung, and Blood Institute.
On November 4, NIH was visited by U.S. Health and Human Services (HHS) Secretary Xavier Becerra and HHS Deputy Secretary Andrea Palm. It was my pleasure to join in welcoming them to our Bethesda, MD campus and sharing some of the exciting research conducted here. In this photo, Secretary Becerra (front left) and Deputy Secretary Palm (standing beside him) visit a lab in NIH’s Dale and Betty Bumpers Vaccine Research Center (VRC) for a briefing on coronavirus vaccine development. Speaking to everyone is Nancy Sullivan (front right), VRC senior investigator. In front of me, joining in the briefing are (from left to right): Tony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID); John Mascola, VRC Director; and Richard A. Koup, VRC Deputy Director. Credit: NIH
On May 26, I testified in person before the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Service (HHS), Education, and Related Agencies. The hearing was titled: National Institutes of Health’s FY22 Budget and the State of Medical Research. Joining me were several NIH institute directors, including Tony Fauci, National Institute of Allergy and Infectious Diseases (NIAID); Diana Bianchi, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Ned Sharpless, National Cancer Institute; Gary Gibbons, National Heart, Lung, and Blood Institute; and Eliseo Perez-Stable, National Institute on Minority Health and Health Disparities.
